Product logins

Find logins to all Clarivate products below.


Myelofibrosis | Niche & Rare Disease Landscape & Forecast | US/EU5 | 2022

Myelofibrosis (MF) is a hematological malignancy characterized by disrupted blood cell production and bone marrow scarring. Symptoms include severe anemia, weakness, fatigue, and splenomegaly. The JAK inhibitors ruxolitinib, fedratinib, and pacritinib are the only drugs approved for MF in the United States and EU5 (pacritinib in the United States only). Although JAK inhibitors offer a therapeutic option, they are associated with high discontinuation rates and are unable to address all MF symptoms. Therefore, significant market opportunity remains for safe and tolerable treatments that can effectively manage the full spectrum of MF symptoms (thus reducing the need for polypharmacy) and that can treat patients with thrombocytopenia and anemia.

QUESTIONS ANSWERED

  • What are the sizes of the U.S. and EU5 diagnosed prevalent and incident primary and secondary MF populations? What are the distributions of risk level among diagnosed incident and prevalent cases of primary MF?
  • What is the current treatment landscape for MF? What are physicians’ experience and satisfaction with current therapies?
  • How have ruxolitinib, fedratinib, and pacritinib been integrated into the MF treatment algorithm? How will these drugs compete in the treatment of MF?
  • What are the key unmet needs and areas of commercial opportunity for MF? How will novel therapies impact the treatment algorithm for MF, and which MF patients will be served by these treatment options in 2031?

PRODUCT DESCRIPTION

Niche & Rare Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.

SOLUTION ENHANCEMENT

Niche & Rare Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.

Related Market Assessment Reports

Report
Systemic Lupus Erythematosus – Landscape & Forecast – Disease Landscape & Forecast (G7)
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that can affect nearly any organ or system in the body. As a result, its course, manifestations, and treatment can be highly…
Report
Diabetic Nephropathy – Current Treatment – Treatment Algorithms: Claims Data Analysis – Diabetic Nephropathy (US)
Diabetic nephropathy (DN), also referred to as diabetic kidney disease, is a common complication of diabetes. The DN drug market comprises a wide variety of antidiabetic and antihypertensive drugs…
Report
Bipolar Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Bipolar Depression (US)
Among bipolar disorder (BPD) patients, depressive episodes are typically more common than manic or mixed episodes; symptoms of bipolar depression include fatigue, insomnia, suicidal ideation, and…
Report
Binge Eating Disorder – Current Treatment – Treatment Algorithms: Claims Data Analysis – Binge Eating Disorder (US)
Binge eating disorder (BED) is a prevalent condition in the United States; it affects millions of individuals across diverse demographics. BED is characterized by recurrent episodes of excessive…
Report
Chronic Obstructive Pulmonary Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Chronic Obstructive Pulmonary Disease (US)
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) / inhaled corticosteroid (ICS) fixed-dose combinations (FDCs)—i.e., Trelegy and Breztri—have been gaining traction in…